Ignite Creation Date:
2025-12-24 @ 10:33 PM
Ignite Modification Date:
2026-05-28 @ 5:56 AM
Study NCT ID:
NCT05216835
Status:
COMPLETED
Last Update Posted:
2025-10-02
First Post:
2022-01-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsed or Refractory Classical Hodgkin Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Pharmacokinetics | View |
| None | Classical Hodgkin Lymphoma (cHL) | View |
| None | Dose Expansion | View |
| None | Dose escalation | View |
| None | r/r cHL | View |
| None | programmed cell death protein-1 (PD-1) | View |
| None | Accelerated titration design (ATD) | View |
| None | T cell immunoglobulin and mucin domain-containing protein-3 (TIM-3) | View |
| None | Modified toxicity probability interval-2 (mTPI-2) | View |
| None | Bispecific antibody | View |
| None | Immunotherapy | View |